Cargando…

Genome-Wide Study of Response to Platinum, Taxane, and Combination Therapy in Ovarian Cancer: In vitro Phenotypes, Inherited Variation, and Disease Recurrence

Background: The standard treatment for epithelial ovarian cancer (EOC) patients with advanced disease is carboplatin-paclitaxel combination therapy following initial debulking surgery, yet there is wide inter-patient variation in clinical response. We sought to identify pharmacogenomic markers relat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fridley, Brooke L., Ghosh, Taraswi M., Wang, Alice, Raghavan, Rama, Dai, Junqiang, Goode, Ellen L., Lamba, Jatinder K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801852/ https://www.ncbi.nlm.nih.gov/pubmed/27047539 http://dx.doi.org/10.3389/fgene.2016.00037

Ejemplares similares

Genome-wide association analysis identified splicing single nucleotide polymorphism in CFLAR predictive of triptolide chemo-sensitivity
por: Chauhan, Lata, et al.
Publicado: (2015)

Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer
por: Raghavan, Rama, et al.
Publicado: (2016)

Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
por: Tian, Hao, et al.
Publicado: (2021)

Hypersensitivity Reactions to Platinum Agents and Taxanes
por: Tsao, Lulu R., et al.
Publicado: (2021)

Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes
por: Earp, Madalene A, et al.
Publicado: (2017)

Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology
por: Kajiyama, Hiroaki, et al.
Publicado: (2014)

Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
por: Liu, Ying, et al.
Publicado: (2015)

Anticancer regimens containing third generation taxanes SB-T-121605 and SB-T-121606 are highly effective in resistant ovarian carcinoma model
por: Seborova, Karolina, et al.
Publicado: (2022)

Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
por: Pecorelli, S., et al.
Publicado: (2010)

Risk of Ovarian Cancer and Inherited Variants in Relapse-Associated Genes
por: Peedicayil, Abraham, et al.
Publicado: (2010)

Platinum drugs and taxanes: can we overcome resistance?
por: Sazonova, Elena V., et al.
Publicado: (2021)

Genome-wide association study for biomarker identification of Rapamycin and Everolimus using a lymphoblastoid cell line system
por: Jiang, Jing, et al.
Publicado: (2013)

TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study
por: Kupryjanczyk, Jolanta, et al.
Publicado: (2008)

Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China
por: Shi, Yin, et al.
Publicado: (2023)

Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients
por: Felisiak-Golabek, Anna, et al.
Publicado: (2011)

Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells
por: Mikuła-Pietrasik, Justyna, et al.
Publicado: (2018)

A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis
por: Liu, Yuanzhi, et al.
Publicado: (2022)

Assessment of Pharmacogenomic Panel Assay for Prediction of Taxane Toxicities: Preliminary Results
por: Di Francia, Raffaele, et al.
Publicado: (2017)

MicroRNA–mRNA Pairs Associated with Outcome in AML: From In Vitro Cell-Based Studies to AML Patients
por: Bhise, Neha S., et al.
Publicado: (2016)

Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer
por: Severi, Leda, et al.
Publicado: (2018)

Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms
por: Imai, Satoshi, et al.
Publicado: (2017)

A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy
por: Liu, Yixin, et al.
Publicado: (2019)

Docetaxel: an alternative taxane in ovarian cancer
por: Katsumata, N
Publicado: (2003)

European American Stratification in Ovarian Cancer Case Control Data: The Utility of Genome-Wide Data for Inferring Ancestry
por: Raska, Paola, et al.
Publicado: (2012)

An ensemble-based Cox proportional hazards regression framework for predicting survival in metastatic castration-resistant prostate cancer (mCRPC) patients
por: Meier, Richard, et al.
Publicado: (2016)

TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma
por: BRACHOVA, PAVLA, et al.
Publicado: (2014)

Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group
por: Ray-Coquard, I, et al.
Publicado: (2009)

Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival
por: Jatoi, Aminah, et al.
Publicado: (2015)

Anti-tumorigenic and Platinum-Sensitizing Effects of Apolipoprotein A1 and Apolipoprotein A1 Mimetic Peptides in Ovarian Cancer
por: Marinho, Aline T., et al.
Publicado: (2019)

Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia
por: Hurkmans, Evelien G. E., et al.
Publicado: (2023)

A Bayesian Network Meta-Analysis for Identifying the Optimal Taxane-Based Chemotherapy Regimens for Treating Gastric Cancer
por: Zhang, Dan, et al.
Publicado: (2019)

Inherited Variants in Regulatory T Cell Genes and Outcome of Ovarian Cancer
por: Goode, Ellen L., et al.
Publicado: (2013)

Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China
por: Nie, Jing, et al.
Publicado: (2023)

Comprehensive Cross-Population Analysis of High-Grade Serous Ovarian Cancer Supports No More Than Three Subtypes
por: Way, Gregory P., et al.
Publicado: (2016)

Assessment of data transformations for model-based clustering of RNA-Seq data
por: Noel-MacDonnell, Janelle R., et al.
Publicado: (2018)

DNA Methylation in Ovarian Cancer Susceptibility
por: Reid, Brett M., et al.
Publicado: (2020)

Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?
por: Patil, Vijay M, et al.
Publicado: (2014)

Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes
por: Tsyganov, Matvey Mihajlovich, et al.
Publicado: (2022)

Oral Administration of Prunella vulgaris L Improves the Effect of Taxane on Preventing the Progression of Breast Cancer and Reduces Its Side Effects
por: Zhao, Jixue, et al.
Publicado: (2018)

Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors
por: Knoerl, Robert, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2l18je542us4jovurjeb6v2guh